OKYO Pharma Ltd: Opaleye Management Inc. discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Opaleye Management Inc. disclosed a stake exceeding 5% in OKYO Pharma Ltd via a Schedule 13G filing with the SEC (accession 0001493152-26-053482). The exact share count and percentage were not specified in the headline disclosure. The filing signals that Opaleye has crossed the 5% passive-investor threshold, making it a reportable beneficial owner in the London-listed biopharma. Investors will watch for further 13G/13D amendments that clarify the precise size of the position and whether the stake remains passive.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
OKYO Pharma Ltd, Opaleye Management Inc.